Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 9Tumor-Agnostic 6Gastrointestinal 4Head & Neck 3Gynecologic 3Thoracic 2Lymphoid 2Genitourinary 2Dermatologic 2Sarcoma 1Plasma cell 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 6Breast Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms by Site 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 33Cetuximab 16Cisplatin 10Radiotherapy 8Paclitaxel 8Docetaxel 8atezolizumab 7Fluorouracil 7cemiplimab 6Drug Therapy 6budigalimab 5Gemcitabine 5Cyclophosphamide 5Blood Specimen Collection 5trametinib 4Pemetrexed 4Nivolumab 4Magnetic Resonance Spectroscopy 4Bleomycin 4Bevacizumab 4palbociclib 3fludarabine 3durvalumab 3dabrafenib 3avelumab 3Trastuzumab 3Oxaliplatin 3Interleukin-2 3Indocyanine Green 3Immunotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × palbociclib × Head & Neck × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

University of California, San Diego

Phase 1 Active not recruiting
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡